Abstract
Inhibition of the renin-angiotensin system contributes to reductions in proteinuria and in progression of chronic kidney disease. Indeed, monotherapy with either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) has been shown to decrease proteinuria and slow the decline of chronic kidney disease, but incompletely. Therefore, there is increasing interest in whether combination strategies will provide more complete blockade of the renin-angiotensin system, which may translate into superior renoprotective and cardioprotective effects compared with either agent alone. There have been several reports on combination strategies. However, the recent report of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) has received much of the attention. The renal outcomes in ONTARGET suggest that combined ACE inhibitor and ARB therapy contributes to a higher rate of adverse renal outcomes than monotherapy. Therefore, this review explores data from ONTARGET in relation to other available evidence on the use of combination therapies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288–296.
Keane WF: Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000, 35:S97–S105.
Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy. Lancet 1997, 349:1857–1863.
Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994, 37:511–516.
Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2–15.
Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.
Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:1100–1108.
Wilmer WA, Robin BH, Hebert CJ, et al.: Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003, 14:3217–3232.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259.
Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.
Menard J, Guyene TT: Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 1991, 18:257–265.
Werner C, Baumhäkel M, Teo KK, et al.: RAS blockade with ARB and ACE inhibitors; current perspective on rationale and patient selection. Clin Res Cardiol 2008, 97:418–431.
Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553.
Law M: Lipids and cardiovascular disease. In Evidence-Based Cardiology. Edited by Yusuf S, Cairns JS, Camm AJ, et al. London: BMJ Books; 1998:191–205.
Yusuf S, Pepine CJ, Graces C, et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173–1178.
Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of survival and ventricular management trial. N Engl J Med 1992, 327:669–677.
Fox KM; European Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.
The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041.
Bhardwaj G: How the antihypertensive losartan was discovered. Expert Opin Drug Discov 2006, 1:609–618.
Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blocker to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799–812.
van de Wal RM, Plokker HW, Lok DJ, et al.: Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006, 106:367–372.
van de Wal RM, van Valdhuist DJ, van Gilst WH, et al.: Addition of an angiotensin receptor blocker to full-dose ACE inhibition; controversial or common sense? Eur Heart J 2005, 26:2361–2367.
Doulton TW, He FJ, MacGregor GA: Systemic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005, 45:880–886.
Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.
McMurray JJ, Ostergen J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors; the CHARM-Added trial. Lancet 2003, 362:767–771.
Pfeffer MA, McMurray JJV, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906.
Lakhdar R, Al-Mallah MH, Lanfear DE: Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and metaanalysis of randomized controlled trials. J Card Fail 2008, 14:181–188.
Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.
Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95–100.
Andersen NH, Poulsen PL, Knudsen ST, et al.: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005, 28:273–277.
Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.
Bakris GL, Ruilope L, Locatelli F, et al.: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007, 72:879–885.
Menne J, Farsang C, Deák L, et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008, 26:1860–1867.
Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48.
MacKinnon M, Shurraw S, Akbari A, et al.: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006, 48:8–20.
Kunz R, Wolbers M, Glass T, Mann JF: The COOPERATE trial: a letter of concern. Lancet 2008, 371:1575–1576.
The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547–1559.
Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
Berl T: Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009, 10:1–8.
Maione A, Nicolucci A, Craig JC, et al.: Protocol of the long-term impact of ras inhibition on cardiorenal outcomes (LIRICO) randomized trial. J Nephrol 2007, 20:646–655.
Fried LF, Duckworth W, Zhang JH, et al.: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361–368.
Schjoedt KJ, Rossing K, Juhl TR, et al.: Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005, 68:2829–2836.
Epstein M, Williams GH, Weinberger M, et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1:940–951.
Remuzzi G, Cattaneo D, Perico N: The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008, 19:1459–1462.
Parving HH, Persson F, Lewis JB, et al., for the AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chaudhary, K., Nistala, R. & Whaley-Connell, A. Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Science Inc 11, 375–381 (2009). https://doi.org/10.1007/s11906-009-0062-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-009-0062-1